Amgen, Inc.

Strand Therapeutics closed a $153 million Series B funding round led by Kinnevik, with participation from major pharmaceutical companies including Eli Lilly, Amgen, and Regeneron Ventures.

Intas Pharmaceuticals and Accord BioPharma have completed the acquisition of UDENYCA (pegfilgrastim-cbqv), a biosimilar to Amgen's Neulasta, from Coherus BioSciences.

Over 18 companies are actively developing 20+ pipeline therapies for vitiligo treatment, with JAK inhibitors leading the charge in late-stage clinical trials.

Kyowa Kirin will present results from the Phase 3 ROCKET IGNITE trial of rocatinlimab, an investigational anti-OX40 monoclonal antibody for moderate-to-severe atopic dermatitis, at the EADV 2025 Annual Meeting in Paris.

Leveragen, a Boston-based biotech company, has announced a strategic collaboration with newly launched Propeller Bio to advance antibody and protein-based therapeutics development.

TCG Labs Soleil, a venture firm collaborating with The Column Group, has raised $400 million to continue launching single-drug biotechnology startups focused on achieving proof-of-concept data for strategic partnerships.

BioVie Inc. appointed Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors to support the company's neurological and liver disease drug development programs.

The FDA has appointed Dr. George Tidmarsh, a former pharmaceutical executive and cancer specialist, to direct the Center for Drug Evaluation and Research, the agency's largest division responsible for reviewing drug safety and effectiveness.

Amgen is conducting a Phase 3 clinical study evaluating etelcalcetide in children and adolescents aged 2 to 18 years with secondary hyperparathyroidism and chronic kidney disease on hemodialysis.

Crescent Biopharma has appointed Jan Pinkas, Ph.D., as chief scientific officer, bringing over two decades of oncology drug development experience including expertise in antibody-drug conjugates.